Cancer Biomarkers Market

Cancer Biomarkers Market applies the most effective of each primary and secondary analysis to weighs upon the competitive landscape and also the outstanding market players expected to dominate Cancer Biomarkers Market place for the forecast 2020– 2025

Advancements in omics techs allow faster acquisition of proteomic, genomic, and metabolomic data, and its incorporation with clinical test info using enhanced bioinformatics software. The omics revolution in the past decade has elevated the applications of biomarkers in biomedical research.

Scope of The Report:

Cancer biomarkers are molecules emitted during the attendance of a particular indication or a tumor in the body to the presence of cancer. These are molecule, substances, or a physical event that show the presence of cancerous cells in the body. These molecules are normally seen in urine, tissues, blood, serum, and other body fluids that show a disease or any abnormal process.

Global cancer biomarkers market is broadly divided by biomolecules, profiling technology, application, cancer type, and geography. By profiling technology, the cancer biomarker industry is divided into imaging technologies, omic technologies, cytogenetics based tests, and immunoassays. Omic technologies section adds up for the biggest cancer biomarker market size. By biomolecules, the cancer biomarker market is divided into protein biomarkers, genetic biomarkers, and glycoprotein biomarkers. Genetic biomarkers section adds up for the biggest cancer biomarker market share. The different cancer type include lung cancer, breast cancer, stomach cancer, colorectal cancer, prostate cancer, and others; among which breast cancer adds up for the biggest cancer biomarker market size. By application, the market can be divided into drug discovery and development, diagnostics, risk assessment, prognostics, and others. Prognostics segments occupies the largest cancer biomarker market share.

Cancer Biomarkers Manufacturers:

The major players included in the global cancer biomarkers market forecast are,

• Abbott Laboratories
• F.Hoffmann-La Roche Ltd
• Novartis AG
• GlaxoSmithKline plc
• Bristol-Myers Squibb
• Merck & Co., Inc.
• Pfizer, Inc.
• Eli Lilly and Company
• Genomic Health, Inc.
• Qiagen N.V.

 

 

Cancer Biomarkers Market Key Segments:

By Profiling Technology 

• Omic Technologies
• Imaging Technologies
• Immunoassays
• Cytogenetics Based Tests

By Biomolecules:

• Genetic Biomarkers
• Protein Biomarkers
• Glycoprotein Biomarkers
• By Cancer Type
• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Prostate Cancer
• Stomach Cancer
• Other Cancers

By Application:

• Diagnostics
• Drug Discovery and Development
• Prognostics
• Risk Assessment
• Others

Rising Popularity Of Tailored Medicine To Power The Growth In The Market

Advancements in omics techs allow faster acquisition of proteomic, genomic, and metabolomic data, and its incorporation with clinical test info using enhanced bioinformatics software. The omics revolution in the past decade has elevated the applications of biomarkers in biomedical research. Also, expansions in high-throughput genomic techs are powering the analysis and identification of polymorphisms and mutations in key genes, thus growing the spectrum of available genomic biomarkers. For example, scientists at the Mayo Clinic have detected the role of mutations in the SPOP gene on the growth of resistance to BET. With these enhancements, the number of obtainable genomic biomarkers for the cancer detection is predicted to increase.

Over the decades, the popularity of tailored medicine has elevated, owing to limitations of standard treatment and diagnosis. Various fields of medicine, from psychiatry to cancer, are leaning towards customized treatments for every patient based on his/her clinical and biological characteristics. The employment of biomarkers has played a major role in specific aspects of tailored medicine. Also, the importance of biomarkers is rising in the field of personalized medicine, with applications in prognosis, diagnosis, and selection of targeted therapies. In terms of measuring disease risk and response to treatment, the continuous identification and development of biomarkers particular to individual patients and a disease is essential for personalized medicine. Hence, the field of tailored medicine is predicted to provide potential development opportunities for players working in the cancer biomarkers market.

Market by Regional Analysis

North America (USA, Canada, Mexico), Europe (UK, France, Germany, Russia, Rest of Europe), Asia-Pacific (China, South Korea, India, Japan, Rest of Asia-Pacific), LAMEA, Latin America, Middle East, Africa

North America And Europe To Lead The Global Cancer Biomarkers Market

Growth in the developed nations of Europe and North America is majorly powered by the increasing number of research studies for the discovery and development of novel biomarkers, high adoption of advanced technologies such as NGS, rising funding and investments from public and private organizations, presence of a large number of pharmaceutical companies, and increasing use of biomarkers in patient stratification and drug development process.